Frontiers in cardiovascular drug discovery. / Volume 3
Cardiovascular agents MEDICAL / Pharmacology
Bentham Science Publishers
2016
EISBN 9781681081632
PREFACE; List of Contributors ; P2Y12-Receptor Antagonists and the Concept of Tailored Strategy ; INTRODUCTION; ADP RECEPTORS; P2Y12 RECEPTOR; P2Y12 INHIBITORS; Thienopyridines; Ticlopidine; Clopidogrel; Prasugrel; Ticagrelor; Cangrelor; Elinogrel; BX 667; THE CONCEPT OF PERSONALIZED THERAPY; Factors Influencing Clopidogrel Variability; Anti-Platelet Function Testing; Platelet Aggregometry; Flow Cytometry; Shear-Dependent Assay; Platelet Counting; Thrombelastography; Anti-Platelet Function Testing & Clinical Impact; Genotype Testing; Genetic Testing & Clinical Impact.
Inter-Individual Variability of New P2Y12 InhibitorsPersonalized Therapy; CONCLUSION; ABBREVIATIONS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Evolution of Heart Failure Pharmacotherapy ; INTRODUCTION; CHRONIC SYSTOLIC HEART FAILURE; β-Blockers; Beta Blockers and Special Populations; Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs) ; Diuretics; Aldosterone Antagonists; Digoxin; Hydralazine/Isosorbide Dinitrate; Ivabradine; Polyunsaturated Fatty Acids (PUFA); Statins; ACUTE DECOMPENSATED HEART FAILURE; Classification; Management; Diuretics.
Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs) β-blockers; Aldosterone Antagonists; Vasopressin Antagonists ; Vasodilators ; Natriuretic Peptides; Inotropes; Novel Agents for Acute Decompensated Heart Failure in Development; HEART FAILURE WITH PRESERVED EJECTION FRACTION; β-Blockers; Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs) ; Calcium Channel Blockers; Digoxin; Aldosterone Antagonists; MISCELLANEOUS DRUG THERAPIES; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES.
V1B or V3 Receptor; V2 Receptor; Oxytocin Receptor; Purinergic Receptors; Down Regulation of Vasopressin Receptors; Systemic Effects of Vasopressin; Renal Effects; Vasoconstrictor Effects; Vasodilator Effects; Effects of Vasopressin on Heart; Endocrine Effects; Effects on Coagulation System; Other Effects; Therapeutic Applications of Vasopressin; Nocturnal Enuresis; Diabetes Insipidus; Bleeding Abnormalities; Oesophageal Varices Haemorrhage; Abdominal Distension & Abdominal X-ray; Vasodilatory Shock States; Hemorrhagic Shock; Other Uses; Future; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS.
Vasopressin and the Cardiovascular System: Receptor Physiology and Clinical Implications INTRODUCTION; HISTORICAL ASPECTS; PHYSIOLOGY OF VASOPRESSIN; Structure of Vasopressin and Related Peptides; Structure of Vasopressin; Structure of Related Peptides; Synthesis of Vasopressin; Metabolism; Factors Affecting Vasopressin Release; Osmoregulation; Baroregulation; Neurohormonal Stimuli; Plasma Levels of Vasopressin; Vasopressin Levels in Health; Vasopressin Levels During Illness; Measurement of Plasma Vasopressin Levels; Vasopressin Receptors; Receptor Structure; Receptor Subtypes; V1A Receptor.
Inter-Individual Variability of New P2Y12 InhibitorsPersonalized Therapy; CONCLUSION; ABBREVIATIONS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Evolution of Heart Failure Pharmacotherapy ; INTRODUCTION; CHRONIC SYSTOLIC HEART FAILURE; β-Blockers; Beta Blockers and Special Populations; Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs) ; Diuretics; Aldosterone Antagonists; Digoxin; Hydralazine/Isosorbide Dinitrate; Ivabradine; Polyunsaturated Fatty Acids (PUFA); Statins; ACUTE DECOMPENSATED HEART FAILURE; Classification; Management; Diuretics.
Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs) β-blockers; Aldosterone Antagonists; Vasopressin Antagonists ; Vasodilators ; Natriuretic Peptides; Inotropes; Novel Agents for Acute Decompensated Heart Failure in Development; HEART FAILURE WITH PRESERVED EJECTION FRACTION; β-Blockers; Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs) ; Calcium Channel Blockers; Digoxin; Aldosterone Antagonists; MISCELLANEOUS DRUG THERAPIES; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES.
V1B or V3 Receptor; V2 Receptor; Oxytocin Receptor; Purinergic Receptors; Down Regulation of Vasopressin Receptors; Systemic Effects of Vasopressin; Renal Effects; Vasoconstrictor Effects; Vasodilator Effects; Effects of Vasopressin on Heart; Endocrine Effects; Effects on Coagulation System; Other Effects; Therapeutic Applications of Vasopressin; Nocturnal Enuresis; Diabetes Insipidus; Bleeding Abnormalities; Oesophageal Varices Haemorrhage; Abdominal Distension & Abdominal X-ray; Vasodilatory Shock States; Hemorrhagic Shock; Other Uses; Future; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS.
Vasopressin and the Cardiovascular System: Receptor Physiology and Clinical Implications INTRODUCTION; HISTORICAL ASPECTS; PHYSIOLOGY OF VASOPRESSIN; Structure of Vasopressin and Related Peptides; Structure of Vasopressin; Structure of Related Peptides; Synthesis of Vasopressin; Metabolism; Factors Affecting Vasopressin Release; Osmoregulation; Baroregulation; Neurohormonal Stimuli; Plasma Levels of Vasopressin; Vasopressin Levels in Health; Vasopressin Levels During Illness; Measurement of Plasma Vasopressin Levels; Vasopressin Receptors; Receptor Structure; Receptor Subtypes; V1A Receptor.
